摘要
目的 分析血管内皮生长因子 (VEGF)及其受体KDR、Flt1在急性髓系白血病 (AML)中的表达和意义。方法 用RT PCR方法检测VEGF及其受体KDR、Flt1mRNA表达 ,ELISA法检测血浆中VEGF水平。结果 13个髓系白血病细胞系VEGF、KDR及Flt1mRNA表达阳性率分别为 10 0 %、5 3 8%和 92 .3 %;39例治疗前AML患者有 32例检测了骨髓单个核细胞 (BMMNC)VEGF、KDR及Flt1mRNA的表达 ,其阳性例数分别为 2 1例 ( 6 5 .6 %)、1例 ( 3.1%)和 17例 ( 5 3 .1%) ,3名健康献髓者BMMNC及 2名健康人骨髓CD34 +细胞均不表达VEGF及其受体。 39例治疗前AML患者血浆VEGF水平为 ( 135 .3±87.9)ng/L ,较 15例治疗后获完全缓解 (CR)的AML患者 [( 80 .6± 36 .9)ng/L]及 12名正常对照 [( 80 .6± 33 .1)ng/L]明显升高 (P =0 .0 2 8,0 .0 0 7)。 39例患者中有 35例接受常规化疗 ,2个疗程后未达CR的15例患者血浆VEGF水平为 ( 188.2± 118.6 )ng/L ,明显高于 2个疗程内获CR的 2 0例患者血浆VEGF水平 [( 10 4.2± 30 .9)ng/L](P =0 .0 0 4)。结论 AML白血病细胞不同程度表达VEGF及其受体mRNA ,AML患者血浆VEGF水平升高 ,VEGF水平影响患者化疗的疗效。
Objective To evaluate the expression of vascular endothelial growth factor(VEGF) and its receptors KDR and Flt1 in patients with acute myeloid leukemia(AML). Methods The expression of VEGF and its receptors mRNA was assayed by RT-PCR, the plasma of VEGF by ELISA. Results In 13 AML cell lines,the expression of VEGF, KDR and Flt1 mRNA were found in 13(100%), 7(53.8%) and 12(92.3%), respectively. There were 21(65.6%), 1(3.1%), and 17(53.1%) of 31 (AML) patients bone marrow mononuclear cells (BMMNCs) expressing VEGF, KDR and Flt1 mRNA, respectively. None of BMMNCs from 3 normal donor and CD 34+ cells from 2 normal donor was found to express VEGF, KDR and Flt1 mRNA. The plasma level of VEGF of 39 patients (new diagnosed, relapsed and secondary-AML)before treatment was (135.3±87.9) ng/L which was significantly higher than that of 15 complete remission(CR) patients (80.6±36.9) ng/L and 12 normal donors (80.6±33.1) μg/L (P=0.028,0.007). The plasma level of VEGF of 15 non-responsive patients was (188.2±118.6) ng/L after two cycles of chemotherapy which was higher than that of 20 CR patients [(104.2±30.9) ng/L] (P=0.004). Conclusion VEGF and its receptors KDR and Flt1 mRNAs were expressed in BMMNCs of AML patients. The plasma level of VEGF directly affected the response to chemotherapy in AML patients.
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2003年第5期249-252,共4页
Chinese Journal of Hematology
基金
攀登计划部分资助项目 ( 95 -专- 10 )
